Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Froehlich

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Guideline-discordant periprocedural interruptions in warfarin therapyLesli E Skolarus, Lewis B Morgenstern, James B Froehlich, et al.
The American Journal of Cardiology|November 11, 2015
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationBrian M Salata, David W Hutton, Deborah A Levine, et al.
Annals of Cardiothoracic Surgery|August 19, 2014
Medical management in type B aortic dissectionToru Suzuki, Kim A Eagle, Eduardo Bossone, et al.
Journal of Vascular Surgery|March 23, 2010
National trends in venous diseaseGeoffrey D Barnes, Sameer Gafoor, Thomas Wakefield, et al.
Case Reports in Medicine|September 25, 2014
AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement InitiativeEric Puroll, Steven T Heidt, Brian Haymart, et al.
Journal of Thrombosis and Thrombolysis|February 23, 2010
Variation in physician deep vein thrombosis prophylaxis attitudes and practices at an academic tertiary care centerErin M Galbraith, Bonnie M Vautaw, Mary Grzybowski, et al.
JAMA Cardiology|January 5, 2017
Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative ExperienceGeoffrey D Barnes, Scott Kaatz, Alexis Lopez, et al.
Coronary Artery Disease|March 21, 2013
Effect of obesity on in-hospital treatment for acute coronary syndrome complicated by new-onset heart failureAudrey H Wu, Kim A Eagle, James B Froehlich, et al.
Vascular Medicine (London, England)|August 23, 2024
Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI<sup>2</sup>) registryNelish Ardeshna, Thane Feldeisen, Xiaowen Kong, et al.
The American Journal of Cardiology|May 8, 2013
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management servicesJulie K Atay, John Fanikos, Geoffrey D Barnes, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Guideline-discordant periprocedural interruptions in warfarin therapyLesli E Skolarus, Lewis B Morgenstern, James B Froehlich, et al.
The American Journal of Cardiology|November 11, 2015
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationBrian M Salata, David W Hutton, Deborah A Levine, et al.
Annals of Cardiothoracic Surgery|August 19, 2014
Medical management in type B aortic dissectionToru Suzuki, Kim A Eagle, Eduardo Bossone, et al.
Journal of Vascular Surgery|March 23, 2010
National trends in venous diseaseGeoffrey D Barnes, Sameer Gafoor, Thomas Wakefield, et al.
Case Reports in Medicine|September 25, 2014
AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement InitiativeEric Puroll, Steven T Heidt, Brian Haymart, et al.
Journal of Thrombosis and Thrombolysis|February 23, 2010
Variation in physician deep vein thrombosis prophylaxis attitudes and practices at an academic tertiary care centerErin M Galbraith, Bonnie M Vautaw, Mary Grzybowski, et al.
JAMA Cardiology|January 5, 2017
Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative ExperienceGeoffrey D Barnes, Scott Kaatz, Alexis Lopez, et al.
Coronary Artery Disease|March 21, 2013
Effect of obesity on in-hospital treatment for acute coronary syndrome complicated by new-onset heart failureAudrey H Wu, Kim A Eagle, James B Froehlich, et al.
Vascular Medicine (London, England)|August 23, 2024
Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI<sup>2</sup>) registryNelish Ardeshna, Thane Feldeisen, Xiaowen Kong, et al.
The American Journal of Cardiology|May 8, 2013
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management servicesJulie K Atay, John Fanikos, Geoffrey D Barnes, et al.
Pageof 13